Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,058

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Open access
Miller, Robert G, Mitchell, J D, Moore, Dan H·2012·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd001447.pub3
Open this paper in CoChat — free account

Abstract

BACKGROUND: Riluzole 100 mg probably prolongs survival in patients with amyotrophic lateral sclerosis by about two months and the safety of the drug is not a major concern. The evidence from randomized controlled trials indicates that patients taking riluzole probably survive longer than patients taking placebo. The beneficial effects are very modest and the drug is expensive. Adverse effects from riluzole are relatively minor and for the most part reversible after stopping the drug. Riluzole has been approved for treatment of patients with amyotrophic lateral sclerosis in many countries but not all. Questions persist about its clinical utility because of high cost, modest efficacy and concern over adverse effects. OBJECTIVES: To examine the efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival. SEARCH STRATEGY: Search of the Cochrane Neuromuscular Disease Group Register for randomized trials and enquiry from authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. The most recent search was November 2002. SELECTION CRITERIA: Randomized trials of adults with diagnosis of amyotrophic lateral sclerosis (ALS), treated with riluzole or placebo. Types of outcome measures: Primary: pooled hazard ratio of tracheostomy-free survival over all time points with riluzole 100 mg. Secondary: per cent mortality as a function of time with riluzole 100 mg and other doses of riluzole; neurologic function, quality of life, muscle strength and adverse events. DATA COLLECTION & ANALYSIS: We identified four eligible randomized trials. Each reviewer graded them for methodological quality. Data extraction was performed by a single reviewer and checked by two others. We obtained some missing data from investigators and regulatory agencies. We performed meta-analyses with Review Manager 4.1 software using a fixed effects model. A test of drug efficacy was based on the Parmar pooled hazard ratio. RESULTS: The three trials examining tracheostomy-free survival included a total of 876 riluzole treated patients and 406 placebo treated patients. The data for tracheostomy-free survival was not available from the fourth trial. The methodological quality was acceptable and the three trials were easily comparable, although one trial included older patients in more advanced stages of amyotrophic lateral sclerosis. Riluzole 100 mg per day provided a benefit for the homogeneous group of patients in the first two trials (p=0.039, hazard ratio 0.80, 95% confidence interval 0.64 to 0.99) and there was no evidence of heterogeneity (p=0.33). When the third trial (which included older and more seriously affected patients) is added, there is evidence of heterogeneity (p<0.0001) and the random effects model, which takes this into account results in the overall treatment effect estimate falling just short of significance (p=0.056, hazard ratio 0.84, 95% confidence interval 0.70 to 1.01). This represents a 9% gain in the probability of surviving one year (57% in the placebo and 66% in the riluzole group). In secondary analyses of survival at separate time points, there was a significant survival advantage with riluzole 100 mg at six, nine, 12 and 15 months, but not at three or 18 months. There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. There were no data on quality of life, but patients treated with riluzole remained in a more moderately affected health state significantly longer than placebo-treated patients (weighted mean difference 35.5 days, 95% confidence interval 5.9 to 65.0). A threefold increase in serum alanine transferase was more frequent in riluzole treated patients than controls (weighted mean difference 2.69, 95% confidence interval 1.65 to 4.38). CONCLUSIONS: Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with ALS. More studies are needed, especially to clarify its effect in older patients (over 75 years), and those with more advanced disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001447.pub3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 45

  1. Bensimon, 1994, A controlled trial of riluzole in amyotrophic lateral sclerosis. The ALS/Riluzole Study Group, New England Journal of Medicine, 330, 585, 10.1056/NEJM199403033300901 · DOI · Paper page
  2. Bensimon, 2002, A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis, Journal of Neurology, 249, 609, 10.1007/s004150200071 · DOI
  3. Lacomblez, 1996, Dose-ranging study of riluzole in amyotrophic lateral sclerosis, Lancet, 347, 1425, 10.1016/S0140-6736(96)91680-3 · DOI · Paper page
  4. Yanagisawa, 1997, Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan, Igakuno Ayumi, 182, 851
  5. Arriada-Mendicoa, 1999, Open label study of riluzole for the treatment of amyotrophic lateral sclerosis, Revista Ecuatoriana de Neurologia, 8, 33
  6. Couratier, 2000, Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS, Revue Neurologique, 156, 357
  7. Desiato, 1999, The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation, Journal of Neurological Sciences, 169, 98, 10.1016/S0022-510X(99)00225-7 · DOI
  8. Graf, 2005, High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study, Journal of Neural Transmission, 112, 649, 10.1007/s00702-004-0220-1 · DOI
  9. Kalra, 1998, Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy, Neuroreport, 9, 1757, 10.1097/00001756-199806010-00016 · DOI
  10. Meininger, 2004, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials, Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, 5, 107, 10.1080/14660820410019602 · DOI
  11. Mitchell, 2006, Audit of outcomes in motor neuron disease (MND) patients treated with riluzole, Amyotrophic lateral sclerosis and other motor neuron disorders, 7, 67, 10.1080/14660820500396984 · DOI
  12. Palma, 2000, An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis, Journal of the Peripheral Nervous System, 5, 46, 10.1046/j.1529-8027.2000.00513-45.x · doi:10.1046/j.1529-8027.2000.00513-45.x
  13. Pongratz, 1999, Open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS), Aktuelle Neurologie, 26, 225, 10.1055/s-2007-1017633 · doi:10.1055/s-2007-1017633
  14. Riviere, 1998, An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole, Archives of Neurology, 55, 526, 10.1001/archneur.55.4.526 · DOI · Paper page
  15. Sojka, 1997, Effects of riluzole on symptom progression in amyotrophic lateral sclerosis, Lancet, 349, 176, 10.1016/S0140-6736(05)60977-4 · DOI
  16. Zoccolella, 2007, Riluzole and amyotrophic lateral sclerosis survival: a population based study in Southern Italy, European Journal of Neurology, 14, 262, 10.1111/j.1468-1331.2006.01575.x · DOI
  17. Borderías-Clau, 2006, Strong suspicion of lung toxicity due to riluzole, Archivos de Bronconeumologia, 42, 42, 10.1016/S1579-2129(06)60113-4 · DOI
  18. Bourke, 2006, Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial, Lancet Neurology, 5, 140, 10.1016/S1474-4422(05)70326-4 · DOI · Paper page
  19. Brooks, 1994, El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors, Journal of Neurological Sciences, 124, 96, 10.1016/0022-510X(94)90191-0 · DOI · Paper page
  20. Brooks, 2001, Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) - Motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study, ALS and other motor neuron diseases, 2, 60
  21. Cassiman, 2003, Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS, Neurology, 61, 1150, 10.1212/01.WNL.0000082385.33604.1D · DOI
  22. Stewart, 2001, The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review, Health Technology Assessment, 5, 1, 10.3310/hta5020 · DOI
  23. Hugon, 1996, Riluzole and ALS therapy, Weiner Medizinische Wochenschrift, 146, 185
  24. Hugon, 1996, ALS therapy: targets for the future, Neurology, 47, 251, 10.1212/WNL.47.6_Suppl_4.251S · doi:10.1212/wnl.47.6_suppl_4.251s
  25. Lacomblez, 1989, A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis, Neurology, 39, 1635, 10.1212/WNL.39.12.1635 · doi:10.1212/wnl.39.12.1635
  26. Logroscino, 2007, Efficacy of riluzole: Who are the patients enrolled in the studies?, Amyotrophic Lateral Sclerosis, 8, 124, 10.1080/17482960701223030 · DOI
  27. McGuire, 1996, Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS, Neurology, 46, 1442, 10.1212/WNL.46.5.1442 · DOI
  28. Meininger, 1997, The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III, Neurology, 244, S22, 10.1007/BF03160577 · doi:10.1007/bf03160577
  29. Meininger, 2004, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, Amyotrophic lateral sclerosis and other motor neuron disorders, 5, 107, 10.1080/14660820410019602 · DOI
  30. Miller, 1996, Clinical trials of riluzole in patients with amyotrophic lateral sclerosis, Neurology, 47, S86
  31. Miller, 1999, Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review), Neurology, 52, 1311, 10.1212/WNL.52.7.1311 · DOI · Paper page
  32. Miller, 2009, Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 73, 1218, 10.1212/WNL.0b013e3181bc0141 · DOI · Paper page
  33. Quality Standards Subcommittee of the American Academy of Neurology, 1997, Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole, Neurology, 49, 657, 10.1212/WNL.49.3.657 · doi:10.1212/wnl.49.3.657
  34. Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Statistics in Medicine, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 · DOI
  35. Remy, 1999, Acute hepatitis after riluzole administration, Journal of Hepatology, 30, 527, 10.1016/S0168-8278(99)80115-9 · DOI
  36. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011
  37. Rodrigo, 2001, Riluzole-induced acute pancreatitis, American Journal of Gastroenterology, 96, 2268, 10.1111/j.1572-0241.2001.03982.x · DOI
  38. Rothstein, 1996, Therapeutic horizons for amyotrophic lateral sclerosis, Current Opinion in Neurobiology, 6, 679, 10.1016/S0959-4388(96)80103-6 · DOI
  39. Rowland, 1994, Riluzole for the treatment of amyotrophic lateral sclerosis - too soon to tell?, New England Journal of Medicine, 330, 636, 10.1056/NEJM199403033300911 · doi:10.1056/nejm199403033300911
  40. Sorenson, 2006, An acute, life-threatening, hypersensitivity reaction to riluzole, Neurology, 67, 2260, 10.1212/01.wnl.0000249182.09143.20 · DOI
  41. Stambler, 1998, Prognostic indicators of survival in ALS, Neurology, 50, 66, 10.1212/WNL.50.1.66 · DOI · Paper page
  42. Traynor, 2001, Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period (1999-2000), Amyotrophic lateral sclerosis and other motor neuron disorders, 2, 43
  43. Turner, 2001, The Kings' Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis and other motor neuron disorders, 2, 43
  44. Weber, 2004, Riluzole-induced neutropenia, Neurology, 62, 1648, 10.1212/01.WNL.0000123015.48097.9A · DOI
  45. Wokke, 1996, Riluzole, Lancet, 348, 795, 10.1016/S0140-6736(96)03181-9 · DOI

Cited by

Metadata

Authors
Miller, R. G., Mitchell, J. D., & Moore, D. H.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2012-03-14
Volume
2012
Issue
3
Pages
191-206
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd001447.pub3
OpenAlex
W3174363935
Cited by
1,058
References
1
FWCI
44.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.